Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Operations (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Cash from Operations for 13 consecutive years, with 6064000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 572.28% to 6064000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 238541000.0 through Dec 2025, up 2167.98% year-over-year, with the annual reading at 238541000.0 for FY2025, 2167.98% up from the prior year.
  • Cash from Operations for Q4 2025 was 6064000.0 at Theravance Biopharma, up from 6508000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 208074000.0 in Q2 2025, with the low at 70547000.0 in Q3 2021.
  • Average Cash from Operations over 5 years is 1909550.0, with a median of 6286000.0 recorded in 2025.
  • Peak annual rise in Cash from Operations hit 4812.89% in 2025, while the deepest fall reached 572.28% in 2025.
  • Over 5 years, Cash from Operations stood at 45250000.0 in 2021, then soared by 233.73% to 60511000.0 in 2022, then plummeted by 101.41% to 854000.0 in 2023, then dropped by 5.62% to 902000.0 in 2024, then plummeted by 572.28% to 6064000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 6064000.0, 6508000.0, and 208074000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.